Tag: ETRM

Blue Horseshoe Stocks: Potential Bottom-Plays & More

 Bottom-Watch Plays

We want to start things off this morning by highlighting a couple of stocks on the higher exchanges that are both currently trading at a low multiple. Stocks that trade on the NASDAQ and NYSE at less than a dollar per share for at least a month can face de-listing procedures, so companies in danger of this tend to go to great lengths to buoy their stock price.

We’re always on the lookout for possible bottom plays so we’re going to be tracking both of the following in coming sessions.

Cobalt International Energy, Inc. CIE – The de-listing alarm bells haven’t quite gone off yet at with CIE, as the PPS just fell below a buck toward the end of last month. The stock also has a recent track record of brief periods of sub-1.00 trading from which it has promptly recovered each time.

This leads us to believe that the company may not even get to the point of receiving a notice from the NYSE before share price sees a recovery. We’re going to want to be on the lookout for that potential rebound.

______

Alliqua Biomedical, Inc. ALQA – In the case of ALQA, a NASDAQ play, the situation is a bit more pressing. Shares fell below the dollar mark at the beginning of September, and the company did receive its ‘failure to satisfy listing requirement’ notice back in October. The PPS has lagged ever since, and has only until the end of April to re-attain the dollar mark, or face delisting.

We’ll be interested to follow along to see what efforts are untaken to once again satisfy listing requirements. In the meantime, the stock has found a reasonably solid base of support off of recent lows, so we’ll be on the lookout for possible rebounds.

Viacom, Inc. VIAB – Options Idea

Our regular readers know full well that we love a good earnings-related options idea, and that’s what we’ve got this morning with Viacom. The company just posted an impressive earnings beat, along with strategic guidance updates that has the stock rocking in the premarket.

We’re going to be keeping our eyes open upon the opening bell, and tracking the activity in the VIAB Weekly $44-45.50 Calls.

Extended Watchlist:
MMEG, SDVI, ISBG, ETRM, CLF, TSLA,

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: Bottom-Plays, Options & More

Novavax, Inc. NVAX

Our first item of interest this morning is going to be NVAX. This play set off our alarms on Friday when the stock was downgraded on the heels of ill-received trial data on the company’s RSV (respiratory syncytial virus) vaccine.

Whenever we see knee-jerk reactions take place, and Friday’s backslide of more than 80% certainly qualifies in that category, we like to place the battered stocks on watch for the subsequent recoveries that occur as often as not.

With the monster gap that Friday’s activity left on the chart (1.20’s to 8.10’s), it will be very interesting to see how the stock responds as we kick off a fresh trading week. Prior to that it had been on a fairly steady four month uptrend that almost reached the 100%-mark. All these factors playing in at once are plenty enough to reserve a slot for NVAX on our radars in coming sessions.

Netflix, Inc. NFLX – Options Idea

We’ve tracked NFLX options to great success on multiple occasion in the past, and today seems like a good time to take another run at it. Along with being on the uptrend for the past six or seven weeks, the stock breached its 200DMA in a bullish manner on Friday, a signal that further advances could be in the cards this week. NFLX is gapping up slightly in the premarket this morning.

In accordance, we want to have an options idea ready and waiting to take advantage should a continued surge be in the cards. The targets we want to zero in on are the NFLX Weekly $99.50-101 Calls for potential swing trades.


APT Systems, Inc. APTY

We alerted our readers to a PR put out by APTY on Friday alluding to the planned purchase of shares out of the open market by the company’s CEO. That coincided with a reasonable amount of momentum that the stock had carried into that session from the one prior.

We mentioned that we liked the chances of the stock seeing some further increases for Friday’s session, and we weren’t disappointed on that front. APTY traded in a solid range from .0032 to .0044, a respectable intraday gain totaling 38%

We’ll remain interested in this play provided it can maintain support above Friday’s swing-low of .0032.

Extended Watchlist:
USLV, CFRX, NWBO, AKBA, ETRM, PTIE